Hormonal
Unimolecular polypharmacology using dual (GLP-1R/GIPR or GLP-1R/GCGR) or triple (GLP-1R/GIPR/GCGR) agonists produces superior weight loss and glycemic control compared to single-agonist GLP-1 receptor agonists.
If you have obesity or type 2 diabetes, newer medications that target multiple hormones (GLP-1, GIP, and Glucagon receptors) like tirzepatide or retatrutide are significantly more effective for weight loss and blood sugar control than older single-target drugs like semaglutide. These are taken as once-weekly injections. While they can cause stomach issues, they are generally well-tolerated and offer superior results. Consult a doctor to see if you qualify for these treatments.
Blockbuster drugs such as tirzepatide and retatrutide have shown unprecedented success in managing obesity and T2DM, demonstrating superior efficacy compared to conventional single agonists.
Why this rating
The paper cites multiple Phase III clinical trials (SURPASS, STEP, SURMOUNT) with large sample sizes and robust statistical significance.
Source
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Qingtong Zhou et al. · The Annual Review of Pharmacology and Toxicology · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →